Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Lopez Pacios

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The Journal of Urology|September 1, 1978
Treatment of pyonephrosis: a comparative studyJ F Jimenez, M A Lopez Pacios, G Llamazares, et al.
International Journal of Cancer|May 29, 1997
Measurement of free PSA in the diagnosis and staging of prostate cancerJ Morote, C X Raventós, J A Lorente, et al.
The Journal of Urology|August 1, 1997
Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./mlJ Morote, C X Raventós, J A Lorente, et al.
American Journal of Clinical Oncology|August 1, 1996
M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladderJ Bellmunt, A Ribas, J Albanell, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The Journal of Urology|September 1, 1978
Treatment of pyonephrosis: a comparative studyJ F Jimenez, M A Lopez Pacios, G Llamazares, et al.
International Journal of Cancer|May 29, 1997
Measurement of free PSA in the diagnosis and staging of prostate cancerJ Morote, C X Raventós, J A Lorente, et al.
The Journal of Urology|August 1, 1997
Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./mlJ Morote, C X Raventós, J A Lorente, et al.
American Journal of Clinical Oncology|August 1, 1996
M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladderJ Bellmunt, A Ribas, J Albanell, et al.
Pageof 1